Donate
Australian & New Zealand Childrens Haematology/Oncology Group

ANZCHOG Children’s Cancer Clinical Trials Repository

Study Title
A randomized Phase III study of vincristine& dactinomycin& cyclophosphamide (VAC) alternating with vincristine and irinotecan (VI) versus VAC/VI plus temsirolimus (TEM) in patients with intermediate risk (IR) rhabdomyosarcoma (RMS)
Protocol ID
ARST1431
Disease (Sub Disease)
Rhabdomyosarcoma
Diagnosis Stage
New diagnosis
Location
NSW, QLD, WA, NZ
Sponsor
National Cancer Institute (NCI)
Trial Status
Open
Sites
The Children's Hospital at Westmead
John Hunter Children's Hospital
Perth Children's Hospital
Queensland Children's Hospital
Sydney Children's Hospital
Christchurch Hospital
Starship Hospital
Study Type
Treatment
Phase
Phase 3
Age Eligibility
under 40 years of age
International registry ID's
NCT02567435
Back to Registry
Study Title A randomized Phase III study of vincristine& dactinomycin& cyclophosphamide (VAC) alternating with vincristine and irinotecan (VI) versus VAC/VI plus temsirolimus (TEM) in patients with intermediate risk (IR) rhabdomyosarcoma (RMS)
Protocol ID ARST1431
Disease (Sub Disease) Rhabdomyosarcoma
Diagnosis Stage New diagnosis
Location NSW / QLD / WA / NZ
Sponsor National Cancer Institute (NCI)
Links https://clinicaltrials.gov/ct2/show/NCT02567435
Trial Status Open
Trial Open Date 09/12/2016
Sites The Children's Hospital at Westmead / John Hunter Children's Hospital / Perth Children's Hospital / Queensland Children's Hospital / Sydney Children's Hospital / Christchurch Hospital / Starship Hospital
Study Type Treatment
Phase Phase 3
Age Eligibility under 40 years of age
International registry ID's NCT02567435